
Myasthenia Gravis
Latest Content
Latest Videos

Shorts
More News

Weekly gefurulimab cut MG-ADL scores by 4.2 points vs 2.6 with placebo at week 26 in adults with generalized myasthenia gravis in the PREVAIL study.

Reductions in antibody function, not IgG titers, distinguishes efgartigimod responders in myasthenia gravis.

University of Virginia Health is tracking efgartigimod durability in generalized myasthenia gravis and how pharmacists help patients get past barriers.

Patients with myasthenia gravis (MG) lived 15 to 19 years longer than those with multiple sclerosis (MS) across 4 datasets.

The phase 3 MINT trial found inebilizumab significantly reduced exacerbations and rescue therapy use in patients with generalized myasthenia gravis.

East Asian patients with generalized myasthenia gravis (gMG) saw meaningful nipocalimab benefits in a Vivacity-MG3 subgroup analysis.

CAR T-cell therapy shows early promise for refractory myasthenia gravis, improving symptoms with mild adverse effects as larger trials loom.

Smartphone remote monitoring captures between-visit symptom changes in myasthenia gravis, spotting week-to-week swings and enabling earlier symptom management than clinic visits.

Interviews with patients living with generalized myasthenia gravis (MG) in the US revealed areas of increased burden in these patients.

A meta-analysis evaluated the efficacy of various monoclonal antibodies in treating patients with myasthenia gravis (MG).

The treatment worked in patients with generalized myasthenia gravis (gMG) regardless of previous immunosuppressive treatment or concomitant use of other gMG treatments.

Efgartigimod has recently been shown effective when investigated to treat ocular myasthenia gravis and juvenile myasthenia gravis.

Carolina Barnett-Tapia, MD, PhD, discusses the results of the ADAPT OCULUS trial, which found promising results for treating patients with ocular myasthenia gravis.

Cemdisiran offers lower treatment burden for patients living with generalized myasthenia gravis, only needing to be taken every 3 months.

Tuan Vu, MD, explains the results of the NIMBLE trial, whose results will be presented at the American Academy of Neurology conference.

Both Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scores improved after treatment.

Poor outcomes could be predicted based on the presence of ectopic germinal centers in the thymus in patients with thymoma-associated myasthenia gravis.

The study, evaluating the efficacy of the combination of efgartigimod alfa and hyaluronidase-qvfc, is the first to specifically evaluate those with ocular myasthenia gravis.







